EnGene squares up to J&J
New detalimogene bladder cancer data send the minnow’s stock up 47%.
Imunon looks for an IL-12 Ovation
The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.
Cellectis gets another bailout
Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.
Royalty Pharma comes to Adstiladrin’s rescue
A royalty financing deal should see this gene therapy launched nine months after its surprise US approval.
